当前位置:首页 - 行情中心 - 康芝药业(300086) - 财务分析 - 利润表

康芝药业

(300086)

  

流通市值:21.83亿  总市值:22.55亿
流通股本:4.36亿   总股本:4.50亿

利润表

报告期2023-09-302023-06-302023-03-312022-12-31
公司类型通用通用通用通用
一、营业总收入451,718,553.98333,024,401.26174,602,090.13535,745,365.83
营业收入451,718,553.98333,024,401.26174,602,090.13535,745,365.83
二、营业总成本480,764,567.55324,152,163.01162,087,454.77688,595,762.59
营业成本196,676,408.09150,257,758.6585,447,653.94263,609,586.61
税金及附加11,334,204.117,573,218.394,159,494.5110,878,784.09
销售费用149,927,281.7788,974,468.5734,466,800.33259,954,892.8
管理费用91,452,663.6856,663,876.5328,439,043.64100,774,177.64
研发费用14,297,192.848,588,101.234,135,560.5328,442,453.02
财务费用17,076,817.0612,094,739.645,438,901.8224,935,868.43
其中:利息费用17,766,49812,324,729.636,204,259.9627,399,653.5
其中:利息收入1,843,902.671,379,333.23805,242.562,798,600.16
加:公允价值变动收益----19,036,212.11
加:投资收益----210,378.65
资产处置收益644,860.53196,246.75-14,819.5198,935.93
资产减值损失(新)704,691.73-3,953,029.34-2,619,639.12-38,315,195.23
信用减值损失(新)7,915,046.178,300,306.85,969,871.12-9,605,504.26
其他收益5,548,619.334,459,220.222,145,400.826,512,494.61
营业利润平衡项目000-
四、营业利润-14,232,795.8117,874,982.6817,995,448.67-213,406,256.47
加:营业外收入35,842.3-3,532.4-6,205.67260,139.79
减:营业外支出393,786.67128,160.4118,158.158,370,854.08
利润总额平衡项目000-
五、利润总额-14,590,740.1817,743,289.8717,971,084.85-221,516,970.76
减:所得税费用8,541,371.413,018,4473,696,182.69-23,565,121.47
六、净利润-23,132,111.5914,724,842.8714,274,902.16-197,951,849.29
持续经营净利润-23,132,111.5914,724,842.8714,274,902.16-197,951,849.29
归属于母公司股东的净利润-20,452,467.416,311,368.2815,414,673.27-187,584,710.74
少数股东损益-2,679,644.19-1,586,525.41-1,139,771.11-10,367,138.55
(一)基本每股收益-0.050.040.03-0.42
(二)稀释每股收益-0.050.040.03-0.42
八、其他综合收益----181,402.71
归属于母公司股东的其他综合收益----181,402.71
九、综合收益总额-23,132,111.5914,724,842.8714,274,902.16-198,133,252
归属于母公司股东的综合收益总额-20,452,467.416,311,368.2815,414,673.27-187,766,113.45
归属于少数股东的综合收益总额-2,679,644.19-1,586,525.41-1,139,771.11-10,367,138.55
公告日期2023-10-272023-08-292023-04-282023-04-24
审计意见(境内)标准无保留意见
TOP↑